Conclusions: Multiple-center large-scale rigorous trials should be considered to evaluate the risk-benefit ratio of immunosuppressive treatment in patients with primary FSGS.
PMID: 22344540 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)